AstraZeneca shares surge 4% on positive COPD trial data

AstraZeneca shares rise 4% after positive data from Tozorakimab Phase III trials for chronic obstructive pulmonary disease treatment. The treatment met its primary endpoint in both trials and showed a favorable safety profile. This reinforces Tozorakimab's potential as a new therapeutic option for COPD patients.